Novartis twice-yearly Legvio in Phase III V-MONO study met primary endpoints

Novartis announced positive topline results from twice-yearly Leqvio in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol, LDL-C, lowering versus both placebo and ezetimibe in patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease, ASCVD, and not receiving lipid-lowering therapy. Novartis plans to present results from this trial at an upcoming medical meeting and share with regulatory agencies including the US Food and Drug Administration.